PDCD1 and hepatocellular carcinoma: Finotonlimab (SCT-I10A) is a humanized immunoglobulin G monoclonal antibody targeting PD-1 that has demonstrated antitumor activity in both murine models and patients.11 Finotonlimab has shown high efficacy and a favorable safety profile in several types of cancer.12–15 SCT510, a bevacizumab biosimilar, also developed by Sinocelltech Ltd., has received authorization for use in China in June 2023.16 Here, we present the findings from a phase II/III study assessing the efficacy and tolerability of finotonlimab and SCT510 in treating late-stage HCC.